Targeting Angiogenesis in Bladder Cancer [News in Brief]
Findings from the phase III RANGE study indicate that adding ramucirumab to docetaxel may improve progression-free survival for patients with advanced or metastatic urothelial carcinoma whose disease is refractory to platinum chemotherapy.
Source: Cancer Discovery - Category: Cancer & Oncology Tags: News in Brief Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Docetaxel | Study | Taxotere